EAN 2021 | Epidemiology and disease characteristics of late-onset MS

Studies have shown that the diagnosis of late-onset multiple sclerosis (MS) has been increasing. Melinda Magyari, MD, PhD, University of Copenhagen, Copenhagen, Denmark, explains that there are currently only a few treatments available for late-onset MS due to fewer treatment opportunities available for older age patients and also immunosenescence, which is prevalent in older age. A lack of evidence for patients being treated with disease modifying therapy, means there is a need for treatments which are specific to individuals with a suppressed immune system. Dr Magyari also highlights the importance of improving diagnosis. This interview took place during the European Academy of Neurology 2021 congress.